AYA Share Price Performance
AU$3.13
2.42 (337.76%)
52.7% undervalued intrinsic discount
AU$6.62
Fair Value
Price AU$3.13
AnalystConsensusTarget AU$6.62
Fair ValueAU$6.62
Share Pricen/a
Artrya Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 19 Fair Values set on narratives written by author
AYA Community Narratives
AN
Fair Value AU$6.62 52.7% undervalued intrinsic discount
US CCTA Adoption And New Reimbursement Will Drive Long Term Cardiac AI Potential
1users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US CCTA Adoption And New Reimbursement Will Drive Long Term Cardiac AI Potential
Catalysts About Artrya Artrya develops AI-powered cardiac imaging software that helps clinicians assess coronary anatomy, plaque and blood flow from CCTA scans. What are the underlying business or industry changes driving this perspective?Read more
38
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AU$6.62
52.7% undervalued intrinsic discount
Fair Value
Profit Margin
43.7%
Future PE
39.8x
Price in 2029
AU$8.33
Trending Discussion
Recently Updated Narratives
AN
US CCTA Adoption And New Reimbursement Will Drive Long Term Cardiac AI Potential
Fair Value: AU$6.62 52.7% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Artrya Limited Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.12
- -60,906.90%
- -67,958.62%
- 0%
About AYA
- Founded
- 2018
- Employees
- n/a
- CEO
- WebsiteView website
Artrya Limited, a medical technology company, engages in the development and commercialization of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia. The company offers Salix, a suite ifcloud-based software that uses artificial intelligence to automate the detection of coronary artery disease from coronary computed tomography angiography scans to identify and manage patients at risk of a heart attack. Artrya Limited was incorporated in 2018 and is based in West Perth, Australia.
